Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas
Authors
Keywords
-
Journal
BLOOD
Volume 119, Issue 16, Pages 3767-3778
Publisher
American Society of Hematology
Online
2012-01-24
DOI
10.1182/blood-2011-09-381988
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
- (2011) L. Alinari et al. BLOOD
- CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease
- (2011) Federica Borghese et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival
- (2011) Idit Shachar et al. LEUKEMIA & LYMPHOMA
- β-Arrestin1 Mediates the Endocytosis and Functions of Macrophage Migration Inhibitory Factor
- (2011) Lishi Xie et al. PLoS One
- Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways
- (2010) R. Stein et al. BLOOD
- Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias
- (2010) P. Gupta et al. BLOOD
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma
- (2010) Robert A. Baiocchi et al. CANCER
- Mantle cell lymphoma in relapse: the role of emerging new drugs
- (2010) Catherine SM Diefenbach et al. CURRENT OPINION IN ONCOLOGY
- High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma
- (2010) Izidore S. Lossos et al. LEUKEMIA & LYMPHOMA
- Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen
- (2010) Sotirios Sachanas et al. LEUKEMIA & LYMPHOMA
- Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
- (2009) E. A. Rossi et al. BLOOD
- Anti-CD20 monoclonal antibodies: historical and future perspectives
- (2009) S. H. Lim et al. HAEMATOLOGICA
- Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
- (2009) A. W. Pawluczkowycz et al. JOURNAL OF IMMUNOLOGY
- MHC II and the Endocytic Pathway: Regulation by Invariant Chain
- (2009) O. J. B. Landsverk et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
- (2008) S. A. Beers et al. BLOOD
- Durable complete responses from therapy with combined epratuzumab and rituximab
- (2008) John P. Leonard et al. CANCER
- Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group
- (2008) David J. Inwards et al. CANCER
- Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics
- (2008) E. A. Rossi et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started